Literature DB >> 18541823

Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion.

Krishna K Gaddam1, Mari K Nishizaka, Monique N Pratt-Ubunama, Eduardo Pimenta, Inmaculada Aban, Suzanne Oparil, David A Calhoun.   

Abstract

BACKGROUND: Resistant hypertension is a common clinical problem and greatly increases the risk of target organ damage.
METHODS: We evaluated the characteristics of 279 consecutive patients with resistant hypertension (uncontrolled despite the use of 3 antihypertensive agents) and 53 control subjects (with normotension or hypertension controlled by using <or=2 antihypertensive medications). Participants were prospectively examined for plasma aldosterone concentration, plasma renin activity, aldosterone to renin ratio, brain-type natriuretic peptide, atrial natriuretic peptide, and 24-hour urinary aldosterone (UAldo), cortisol, sodium, and potassium values while adhering to a routine diet.
RESULTS: Plasma aldosterone (P < .001), aldosterone to renin ratio (P < .001), 24-hour UAldo (P = .02), brain-type natriuretic peptide (P = .007), and atrial natriuretic peptide (P = .001) values were higher and plasma renin activity (P = .02) and serum potassium (P < .001) values were lower in patients with resistant hypertension vs controls. Of patients with resistant hypertension, men had significantly higher plasma aldosterone (P = .003), aldosterone to renin ratio (P = .02), 24-hour UAldo (P < .001), and urinary cortisol (P < .001) values than women. In univariate linear regression analysis, body mass index (P = .01), serum potassium (P < .001), urinary cortisol (P < .001), urinary sodium (P = .02), and urinary potassium (P < .001) values were correlated with 24-hour UAldo levels. Serum potassium (P = .001), urinary potassium (P < .001), and urinary sodium (P = .03) levels were predictors of 24-hour UAldo levels in multivariate modeling.
CONCLUSIONS: Aldosterone levels are higher and there is evidence of intravascular volume expansion (higher brain-type and atrial natriuretic peptide levels) in patients with resistant hypertension vs controls. These differences are most pronounced in men. A significant correlation between 24-hour urinary aldosterone levels and cortisol excretion suggests that a common stimulus, such as corticotropin, may underlie the aldosterone excess in patients with resistant hypertension.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18541823      PMCID: PMC2748247          DOI: 10.1001/archinte.168.11.1159

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  30 in total

1.  Resistant hypertension: diagnosis and management.

Authors:  R W Gifford; R C Tarazi
Journal:  Ann Intern Med       Date:  1978-05       Impact factor: 25.391

2.  Low-renin status in therapy-resistant hypertension: a clue to efficient treatment.

Authors:  Ivar K Eide; Peter A Torjesen; Anders Drolsum; Almira Babovic; Nils P Lilledahl
Journal:  J Hypertens       Date:  2004-11       Impact factor: 4.844

3.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

4.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.

Authors:  Carl J Pepine; Eileen M Handberg; Rhonda M Cooper-DeHoff; Ronald G Marks; Peter Kowey; Franz H Messerli; Giuseppe Mancia; José L Cangiano; David Garcia-Barreto; Matyas Keltai; Serap Erdine; Heather A Bristol; H Robert Kolb; George L Bakris; Jerome D Cohen; William W Parmley
Journal:  JAMA       Date:  2003-12-03       Impact factor: 56.272

5.  Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.

Authors:  Ihab Hajjar; Theodore A Kotchen
Journal:  JAMA       Date:  2003-07-09       Impact factor: 56.272

6.  Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study.

Authors:  Ramachandran S Vasan; Jane C Evans; Emelia J Benjamin; Daniel Levy; Martin G Larson; Johan Sundstrom; Joanne M Murabito; Flora Sam; Wilson S Colucci; Peter W F Wilson
Journal:  Hypertension       Date:  2004-03-08       Impact factor: 10.190

7.  Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region.

Authors:  B Strauch; T Zelinka; M Hampf; R Bernhardt; J Widimsky
Journal:  J Hum Hypertens       Date:  2003-05       Impact factor: 3.012

8.  Serum aldosterone and the incidence of hypertension in nonhypertensive persons.

Authors:  Ramachandran S Vasan; Jane C Evans; Martin G Larson; Peter W F Wilson; James B Meigs; Nader Rifai; Emelia J Benjamin; Daniel Levy
Journal:  N Engl J Med       Date:  2004-07-01       Impact factor: 91.245

9.  Plasma release of atrial natriuretic peptide in response to blood volume expansion.

Authors:  J V Anderson; N D Christofides; S R Bloom
Journal:  J Endocrinol       Date:  1986-04       Impact factor: 4.286

10.  Human adipocytes secrete mineralocorticoid-releasing factors.

Authors:  M Ehrhart-Bornstein; V Lamounier-Zepter; A Schraven; J Langenbach; H S Willenberg; A Barthel; H Hauner; S M McCann; W A Scherbaum; S R Bornstein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-12       Impact factor: 11.205

View more
  93 in total

1.  Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension.

Authors:  Carolina C Gonzaga; Krishna K Gaddam; Mustafa I Ahmed; Eduardo Pimenta; S Justin Thomas; Susan M Harding; Suzanne Oparil; Stacey S Cofield; David A Calhoun
Journal:  J Clin Sleep Med       Date:  2010-08-15       Impact factor: 4.062

Review 2.  Effect of Antihypertensive Medications on the Severity of Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis.

Authors:  Kiran Khurshid; Jonathan Yabes; Patricia M Weiss; Sushma Dharia; Lee Brown; Mark Unruh; Manisha Jhamb
Journal:  J Clin Sleep Med       Date:  2016-08-15       Impact factor: 4.062

3.  [Resistant hypertension : What is it?].

Authors:  F C Luft
Journal:  Internist (Berl)       Date:  2015-03       Impact factor: 0.743

4.  Prevalence and Comorbidities of Resistant Hypertension: A Collaborative Population-Based Observational Study.

Authors:  Simone Romano; Chiara Idolazzi; Cristiano Fava; Luigi Fondrieschi; Mario Celebrano; Pietro Delva; Lorella Branz; Angela Donato; Andrea Dalbeni; Pietro Minuz
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-06-29

5.  Hypertension: Endothelin-receptor antagonists for treating hypertension.

Authors:  Matthew R Weir
Journal:  Nat Rev Nephrol       Date:  2010-04       Impact factor: 28.314

6.  Effectiveness of Renal Denervation in Resistant Hypertension: A Meta-Analysis of 11 Controlled Studies.

Authors:  Marco Pappaccogli; Michele Covella; Elena Berra; Chiara Fulcheri; Silvia Di Monaco; Elisa Perlo; Jacopo Burrello; Silvia Monticone; Denis Rossato; Franco Rabbia; Franco Veglio
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-05-11

Review 7.  Resistant hypertension and hyperaldosteronism.

Authors:  Carolina C Gonzaga; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

Review 8.  Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review.

Authors:  Andrew S Bomback; Philip J Klemmer
Journal:  Am J Nephrol       Date:  2009-03-20       Impact factor: 3.754

9.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

10.  Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report.

Authors:  K Gaddam; E Pimenta; S J Thomas; S S Cofield; S Oparil; S M Harding; D A Calhoun
Journal:  J Hum Hypertens       Date:  2009-12-17       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.